DK3072525T3 - Fremgangsmåder til reducering af niveauer af basofile celler - Google Patents
Fremgangsmåder til reducering af niveauer af basofile celler Download PDFInfo
- Publication number
- DK3072525T3 DK3072525T3 DK15190653.4T DK15190653T DK3072525T3 DK 3072525 T3 DK3072525 T3 DK 3072525T3 DK 15190653 T DK15190653 T DK 15190653T DK 3072525 T3 DK3072525 T3 DK 3072525T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- administration
- antibody
- subject
- doses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Monoklonalt, humaniseret antistof, der binder IL-5R, til anvendelse til reducering af antallene af basofile celler hos et menneske ved hjælp af parenteral administration af antistoffet til personen ved fra 0,01 til 0,25 mg/kg, hvor antistoffet omfatter aminosyresekvenserne ifølge SEQ ID NO: 1 og 3 og en immunoglobulin-Fc-region, der ikke omfatter fucose.
2. Antistof til anvendelse ifølge krav 1, hvor antistoffet binder specifikt til IL-5R-a-kæden.
3. Antistof til anvendelse ifølge krav 1 eller krav 2, hvor reduktionen af basofile celler i perferifert blod er reversibel.
4. Antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor antallet af basofile celler i perifert blod fra personens kredsløb er reduceret til et niveau på mellem 0 og 10 basofile celler/mm3.
5. Antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor der er en reduktion efter administration i absolut antal af basofile celler på mindst 5, mindst 10, mindst 15, mindst 20, mindst 25, mindst 30, mindst 35, mindst 40, mindst 45, mindst 50, mindst 55, mindst 60, mindst 65 eller mindst 70 basofile celler/mm3.
6. Antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor personens absolutte antal af basofile celler før administration er mellem 5 og 500 basofile celler/mm3.
7. Antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor personens absolutte antal af basofile celler før administration er mindst 5, mindst 10, mindst 15, mindst 20, mindst 30, mindst 50, mindst 60 eller mindst 100 basofile celler/mm3.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92442207P | 2007-05-14 | 2007-05-14 | |
US92483207P | 2007-06-01 | 2007-06-01 | |
US93500507P | 2007-07-20 | 2007-07-20 | |
US6461208P | 2008-03-14 | 2008-03-14 | |
EP08779619.9A EP2068927B1 (en) | 2007-05-14 | 2008-05-14 | Methods of reducing eosinophil levels |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3072525T3 true DK3072525T3 (da) | 2018-04-30 |
Family
ID=40122040
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08779619.9T DK2068927T3 (da) | 2007-05-14 | 2008-05-14 | Fremgangsmåder til reducering af eosinofilniveauer |
DK15190653.4T DK3072525T3 (da) | 2007-05-14 | 2008-05-14 | Fremgangsmåder til reducering af niveauer af basofile celler |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08779619.9T DK2068927T3 (da) | 2007-05-14 | 2008-05-14 | Fremgangsmåder til reducering af eosinofilniveauer |
Country Status (25)
Country | Link |
---|---|
US (3) | US20100291073A1 (da) |
EP (2) | EP3072525B1 (da) |
JP (6) | JP2010527356A (da) |
KR (3) | KR101588061B1 (da) |
CN (2) | CN101848732B (da) |
AU (3) | AU2008255027B2 (da) |
BR (1) | BRPI0811526A2 (da) |
CA (2) | CA2986531C (da) |
CY (2) | CY1117594T1 (da) |
DK (2) | DK2068927T3 (da) |
ES (2) | ES2558689T3 (da) |
HK (3) | HK1132658A1 (da) |
HR (2) | HRP20160058T1 (da) |
HU (2) | HUE026728T2 (da) |
IL (2) | IL202102A (da) |
LT (1) | LT3072525T (da) |
MX (3) | MX2009012341A (da) |
NO (1) | NO3072525T3 (da) |
NZ (2) | NZ741494A (da) |
PL (2) | PL2068927T3 (da) |
PT (2) | PT3072525T (da) |
RU (2) | RU2519227C2 (da) |
SG (2) | SG10202000728UA (da) |
SI (2) | SI2068927T1 (da) |
WO (1) | WO2008143878A1 (da) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101715443A (zh) | 2007-03-14 | 2010-05-26 | 诺普神经科学股份有限公司 | 手性纯化的取代的苯并噻唑二胺的合成 |
KR101588061B1 (ko) * | 2007-05-14 | 2016-01-25 | 메디뮨 엘엘씨 | 호산구 수준을 감소시키는 방법 |
JP2012500283A (ja) | 2008-08-19 | 2012-01-05 | ノップ ニューロサイエンシーズ、インク. | (r)−プラミペキソールを使用した組成物並びにその方法 |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
LT3590949T (lt) | 2010-10-01 | 2022-07-25 | Modernatx, Inc. | Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas |
US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
WO2012158954A1 (en) * | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
MX354267B (es) | 2011-10-03 | 2018-02-21 | Moderna Therapeutics Inc Star | Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos. |
KR20140097217A (ko) * | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
PT3019167T (pt) | 2013-07-12 | 2021-03-04 | Knopp Biosciences Llc | Tratamento de níveis elevados de eosinófilos e/ou basófilos |
WO2015023508A2 (en) * | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for improving asthma symptoms using benralizumab |
ES2716906T3 (es) * | 2013-08-12 | 2019-06-17 | Astrazeneca Ab | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab |
AU2014306959B2 (en) * | 2013-08-12 | 2019-11-21 | Astrazeneca Ab | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
US9642840B2 (en) | 2013-08-13 | 2017-05-09 | Knopp Biosciences, Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
HUE055850T2 (hu) | 2013-08-13 | 2022-01-28 | Knopp Biosciences Llc | Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
US20150104447A1 (en) * | 2013-10-15 | 2015-04-16 | Medimmune, Llc | Methods for treating chronic obstructive pulmonary disease using benralizumab |
SG11201603206UA (en) * | 2013-10-24 | 2016-05-30 | Medimmune Llc | Stable, aqueous antibody formulations |
RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
EP3145543A4 (en) * | 2014-05-23 | 2017-12-13 | Celldex Therapeutics, Inc. | Treatment of eosinophil or mast cell related disorders |
US10479836B2 (en) | 2015-06-01 | 2019-11-19 | National University Corporation University Of Toyama | Method for treating pulmonary hypertension with interleukin-5 receptor antibody |
WO2017077391A2 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
CN109942706A (zh) | 2017-12-21 | 2019-06-28 | 三生国健药业(上海)股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
WO2019133818A1 (en) * | 2017-12-29 | 2019-07-04 | Cornell University | Gene therapy for eosinohilic disorders |
CN113227359A (zh) | 2018-08-24 | 2021-08-06 | 耶达研究及发展有限公司 | 调节m2巨噬细胞极化的方法及其在治疗中的用途 |
TW202110479A (zh) | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
TW202214692A (zh) | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业(上海)股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
CN116887860A (zh) | 2020-12-17 | 2023-10-13 | 阿斯利康(瑞典)有限公司 | 抗il5r抗体配制品 |
CA3232203A1 (en) * | 2021-09-22 | 2023-03-30 | James MATTHAEI | Il5ra cell surface markers |
CN115671140B (zh) * | 2022-10-31 | 2024-03-22 | 华中科技大学同济医学院附属同济医院 | 丙酸痤疮杆菌在制备治疗鼻息肉的药品中的应用 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US633187A (en) | 1898-12-20 | 1899-09-19 | Alba L Holmes | Meter-box. |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ATE175118T1 (de) | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2074825C (en) | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
DE69334305D1 (de) | 1992-08-21 | 2010-01-28 | Univ Bruxelles | Immunoglobuline ohne leichte Ketten |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6465616B1 (en) | 1994-04-08 | 2002-10-15 | Bresagen Limited | Interleukin-5 antagonist |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
US5677280A (en) | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
CA2205007C (en) * | 1995-09-11 | 2010-12-14 | Masamichi Koike | Antibody against human interleukin-5 receptor .alpha. chain |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US7033840B1 (en) * | 1999-11-09 | 2006-04-25 | Sri International | Reaction calorimeter and differential scanning calorimeter for the high-throughput synthesis, screening and characterization of combinatorial libraries |
AU2161501A (en) | 1999-11-29 | 2001-06-25 | Unilever Plc | Immobilized single domain antigen-binding molecules |
US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
AU2001232304A1 (en) | 2000-02-15 | 2001-08-27 | Kyowa Hakko Kogyo Co. Ltd. | Eosinophil-specific apoptosis inducer |
JP2003530847A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
EP1272526A4 (en) | 2000-04-13 | 2004-10-13 | Univ Rockefeller | REINFORCING ANTIBODY-IMMUNE RESPONSE |
MXPA03000105A (es) | 2000-06-28 | 2004-09-13 | Glycofi Inc | Metodo para producir glicoproteinas modificadas. |
US20060257399A1 (en) | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
US7632983B2 (en) | 2000-07-31 | 2009-12-15 | Biolex Therapeutics, Inc. | Expression of monoclonal antibodies in duckweed |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
AU2002307037B2 (en) | 2001-04-02 | 2008-08-07 | Biogen Idec Inc. | Recombinant antibodies coexpressed with GnTIII |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
EP2042517B1 (en) | 2002-09-27 | 2012-11-14 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US20060147523A1 (en) * | 2002-10-16 | 2006-07-06 | Alan Fergusson | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
EP1688437A4 (en) * | 2003-10-08 | 2007-09-26 | Kyowa Hakko Kogyo Kk | SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR |
US20050226867A1 (en) | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
US20050095602A1 (en) * | 2003-11-04 | 2005-05-05 | West Jason A. | Microfluidic integrated microarrays for biological detection |
EA025962B1 (ru) | 2003-11-05 | 2017-02-28 | Роше Гликарт Аг | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
AU2004299833B2 (en) | 2003-12-10 | 2009-05-07 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
CN103351434B (zh) * | 2004-07-15 | 2015-09-30 | 赞科股份有限公司 | 优化的Fc变体 |
AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
EP1831256A1 (en) | 2004-12-23 | 2007-09-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a galglcnacman5glcnac2 glycoform |
WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
WO2007041635A2 (en) * | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
PT1945665E (pt) | 2005-10-21 | 2012-04-20 | Genzyme Corp | Terapêuticas à base de anticorpos com atividade adcc reforçada |
KR101588061B1 (ko) * | 2007-05-14 | 2016-01-25 | 메디뮨 엘엘씨 | 호산구 수준을 감소시키는 방법 |
-
2008
- 2008-05-14 KR KR1020097025886A patent/KR101588061B1/ko active IP Right Grant
- 2008-05-14 SG SG10202000728UA patent/SG10202000728UA/en unknown
- 2008-05-14 NZ NZ741494A patent/NZ741494A/en unknown
- 2008-05-14 KR KR1020167000810A patent/KR101827179B1/ko active IP Right Grant
- 2008-05-14 EP EP15190653.4A patent/EP3072525B1/en active Active
- 2008-05-14 ES ES08779619.9T patent/ES2558689T3/es active Active
- 2008-05-14 CN CN2008800233678A patent/CN101848732B/zh active Active
- 2008-05-14 JP JP2010508412A patent/JP2010527356A/ja active Pending
- 2008-05-14 NO NO15190653A patent/NO3072525T3/no unknown
- 2008-05-14 PT PT151906534T patent/PT3072525T/pt unknown
- 2008-05-14 PL PL08779619T patent/PL2068927T3/pl unknown
- 2008-05-14 MX MX2009012341A patent/MX2009012341A/es active IP Right Grant
- 2008-05-14 SI SI200831561A patent/SI2068927T1/sl unknown
- 2008-05-14 CA CA2986531A patent/CA2986531C/en active Active
- 2008-05-14 RU RU2009146125/15A patent/RU2519227C2/ru active
- 2008-05-14 DK DK08779619.9T patent/DK2068927T3/da active
- 2008-05-14 AU AU2008255027A patent/AU2008255027B2/en active Active
- 2008-05-14 CN CN201310170361.6A patent/CN103223167B/zh active Active
- 2008-05-14 DK DK15190653.4T patent/DK3072525T3/da active
- 2008-05-14 SI SI200831949T patent/SI3072525T1/en unknown
- 2008-05-14 MX MX2020011303A patent/MX2020011303A/es unknown
- 2008-05-14 CA CA2685222A patent/CA2685222C/en active Active
- 2008-05-14 NZ NZ599278A patent/NZ599278A/en unknown
- 2008-05-14 HU HUE08779619A patent/HUE026728T2/en unknown
- 2008-05-14 PT PT87796199T patent/PT2068927E/pt unknown
- 2008-05-14 ES ES15190653.4T patent/ES2666165T3/es active Active
- 2008-05-14 BR BRPI0811526A patent/BRPI0811526A2/pt not_active Application Discontinuation
- 2008-05-14 HU HUE15190653A patent/HUE036885T2/hu unknown
- 2008-05-14 WO PCT/US2008/006156 patent/WO2008143878A1/en active Application Filing
- 2008-05-14 SG SG10201503254TA patent/SG10201503254TA/en unknown
- 2008-05-14 PL PL15190653T patent/PL3072525T3/pl unknown
- 2008-05-14 LT LTEP15190653.4T patent/LT3072525T/lt unknown
- 2008-05-14 EP EP08779619.9A patent/EP2068927B1/en active Active
- 2008-05-14 KR KR1020157023657A patent/KR20150107890A/ko not_active Application Discontinuation
- 2008-05-14 US US12/600,017 patent/US20100291073A1/en not_active Abandoned
-
2009
- 2009-11-12 IL IL202102A patent/IL202102A/en active IP Right Grant
- 2009-11-12 HK HK09110575.3A patent/HK1132658A1/zh unknown
-
2011
- 2011-03-10 HK HK14100691.6A patent/HK1187542A1/xx unknown
- 2011-03-10 HK HK11102438.3A patent/HK1148220A1/xx unknown
- 2011-07-06 US US13/177,221 patent/US8501176B2/en active Active
-
2013
- 2013-07-03 US US13/934,271 patent/US9815895B2/en active Active
- 2013-12-20 AU AU2013273774A patent/AU2013273774B2/en active Active
-
2014
- 2014-02-14 RU RU2014105496A patent/RU2618455C2/ru active
-
2015
- 2015-07-27 IL IL240179A patent/IL240179B/en active IP Right Grant
- 2015-07-31 JP JP2015151502A patent/JP2016034940A/ja active Pending
- 2015-08-27 MX MX2015011174A patent/MX2015011174A/es active IP Right Grant
-
2016
- 2016-01-19 HR HRP20160058TT patent/HRP20160058T1/hr unknown
- 2016-01-20 CY CY20161100052T patent/CY1117594T1/el unknown
- 2016-12-12 AU AU2016273830A patent/AU2016273830B2/en active Active
-
2017
- 2017-07-12 JP JP2017135920A patent/JP2018021017A/ja active Pending
-
2018
- 2018-04-17 HR HRP20180611TT patent/HRP20180611T1/hr unknown
- 2018-04-27 CY CY20181100445T patent/CY1120417T1/el unknown
-
2019
- 2019-07-11 JP JP2019129029A patent/JP2019194242A/ja active Pending
-
2021
- 2021-10-21 JP JP2021172302A patent/JP2022023157A/ja active Pending
-
2023
- 2023-08-24 JP JP2023136193A patent/JP2023159349A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016273830B2 (en) | Methods of reducing eosinophil levels | |
JP2020156506A (ja) | 抗il−36r抗体 | |
JP2021503888A (ja) | 抗cxcr5抗体、その組成物及びその使用 | |
TW202227489A (zh) | 抗par-2抗體及其使用方法 | |
KR20210119448A (ko) | Cd31 경쟁인자(competitor) 및 이의 용도 | |
NZ724413B2 (en) | Methods of reducing basophil levels | |
NZ724413A (en) | Methods of reducing basophil levels | |
WO2022077021A1 (en) | CD1a ANTIBODIES AND USES THEREOF | |
KR20230145929A (ko) | CD1a 항체 및 그의 용도 | |
WO2023245178A1 (en) | Methods of detecting ddr1 phosphorylation |